Surrozen, Inc./DE

SRZN Nasdaq CIK: 0001824893

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 171 OYSTER POINT BLVD, SOUTH SAN FRANCISCO, CA, 94080
Mailing Address 171 OYSTER POINT BLVD, SOUTH SAN FRANCISCO, CA, 94080
Phone 650-475-2820
Fiscal Year End 1231
EIN 301374889

Financial Overview

FY2025

-$63.56M
Net Income
$-21.67
EPS

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report March 25, 2026 View on SEC
10-K Annual financial report March 23, 2026 View on SEC
S-3 Shelf registration for future offerings March 23, 2026 View on SEC
8-K Current report of material events March 23, 2026 View on SEC
4 Insider stock transaction report March 16, 2026 View on SEC
4 Insider stock transaction report February 18, 2026 View on SEC
4 Insider stock transaction report February 18, 2026 View on SEC
4 Insider stock transaction report February 18, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 17, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 17, 2026 View on SEC

Annual Reports

10-K March 23, 2026
  • Secured major collaboration and license agreements, including a significant partnership with Biogen (BI) extending through 2025 and possibly into 2026.
  • Utilizes license agreements with Stanford University, integrating top-tier academic research into their development.
View Analysis

Insider Trading

STRONG BUY 5 insiders 54 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.